Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$25.62 - $37.07 $5.05 Million - $7.3 Million
-197,000 Reduced 75.19%
65,000 $2.31 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $2.03 Million - $3.88 Million
127,000 Added 94.07%
262,000 $7.79 Million
Q2 2023

Aug 14, 2023

BUY
$15.73 - $23.6 $550,550 - $826,000
35,000 Added 35.0%
135,000 $2.43 Million
Q1 2023

May 15, 2023

BUY
$15.31 - $21.1 $1.53 Million - $2.11 Million
100,000 New
100,000 $1.61 Million
Q2 2022

Aug 15, 2022

SELL
$16.49 - $27.64 $3.36 Million - $5.64 Million
-204,000 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $2.18 Million - $3.6 Million
-127,000 Reduced 38.37%
204,000 $4.48 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $2.67 Million - $3.92 Million
138,000 Added 71.5%
331,000 $9.4 Million
Q3 2021

Nov 17, 2021

SELL
$16.88 - $25.23 $3.88 Million - $5.8 Million
-230,000 Reduced 54.37%
193,000 $4.06 Million
Q3 2021

Nov 15, 2021

SELL
$16.88 - $25.23 $1.86 Million - $2.78 Million
-110,033 Reduced 20.64%
423,000 $11.3 Million
Q2 2021

Aug 13, 2021

BUY
$15.9 - $21.15 $2.72 Million - $3.62 Million
171,103 Added 47.28%
533,033 $10 Million
Q4 2020

Feb 16, 2021

BUY
$12.08 - $17.46 $4.37 Million - $6.32 Million
361,930 New
361,930 $5.11 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.